Literature DB >> 11255939

Cocaine withdrawal symptoms and initial urine toxicology results predict treatment attrition in outpatient cocaine dependence treatment.

K M Kampman1, A I Alterman, J R Volpicelli, I Maany, E S Muller, D D Luce, E M Mulholland, A F Jawad, G A Parikh, F D Mulvaney, R M Weinrieb, C P O'Brien.   

Abstract

This study evaluated the ability of cocaine withdrawal symptoms, measured by the Cocaine Selective Severity Assessment (CSSA) and initial urine toxicology results, to predict treatment attrition among 128 cocaine dependent veterans participating in a 4-week day hospital treatment program. The CSSA was administered and a urine toxicology screen was obtained at intake and at the start of the day hospital (about 1 week later). The combination of a positive urine toxicology screen and a high CSSA score at intake predicted failure to complete treatment. Urine toxicology results at the start of the day hospital, but not at intake, predicted failure to complete treatment. Among participants without other psychiatric illness, high CSSA scores at intake predicted failure to complete treatment. The presence of cocaine withdrawal symptoms and a positive urine toxicology screen are clinically useful predictors of treatment attrition.

Entities:  

Mesh:

Year:  2001        PMID: 11255939     DOI: 10.1037/0893-164x.15.1.52

Source DB:  PubMed          Journal:  Psychol Addict Behav        ISSN: 0893-164X


  46 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

Review 2.  Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: a novel treatment strategy.

Authors:  Tong H Lee; Steven T Szabo; J Corey Fowler; Paolo Mannelli; O Barry Mangum; Wayne F Beyer; Ashwin Patkar; William C Wetsel
Journal:  Drug Alcohol Depend       Date:  2012-02-21       Impact factor: 4.492

Review 3.  Neuropsychiatric effects of cocaine use disorders.

Authors:  Charles U Nnadi; Olubansile A Mimiko; Henry L McCurtis; Jean Lud Cadet
Journal:  J Natl Med Assoc       Date:  2005-11       Impact factor: 1.798

Review 4.  Illusory predictors: Generalizability of findings in cocaine treatment retention research.

Authors:  Angela L Stotts; Marc E Mooney; Shelly L Sayre; Meredith Novy; Joy M Schmitz; John Grabowski
Journal:  Addict Behav       Date:  2007-05-03       Impact factor: 3.913

5.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

6.  Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women.

Authors:  Helen C Fox; Rajita Sinha
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 7.  Review. Evidence-based treatments of addiction.

Authors:  Charles P O'Brien
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-10-12       Impact factor: 6.237

8.  Effects of major depressive disorder and attention-deficit/hyperactivity disorder on the outcome of treatment for cocaine dependence.

Authors:  Frances R Levin; Adam Bisaga; Wilfrid Raby; Efrat Aharonovich; Eric Rubin; John Mariani; Daniel J Brooks; Fatima Garawi; Edward V Nunes
Journal:  J Subst Abuse Treat       Date:  2007-06-15

9.  Insomnia severity during early abstinence is related to substance use treatment completion in adults enrolled in an intensive outpatient program.

Authors:  Allison K Wilkerson; Gregory L Sahlem; Brandon S Bentzley; Jessica Lord; Joshua P Smith; Richard O Simmons; Thomas W Uhde; Sarah W Book
Journal:  J Subst Abuse Treat       Date:  2019-06-07

10.  Reduced emotional signs of opiate withdrawal in rats selectively bred for low (LoS) versus high (HiS) saccharin intake.

Authors:  Anna K Radke; Nathan A Holtz; Jonathan C Gewirtz; Marilyn E Carroll
Journal:  Psychopharmacology (Berl)       Date:  2012-12-20       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.